ENO2 and cancer: Stringent screening criteria were applied, including the exclusion of individuals with known or suspected ProGRP-related conditions—such as cancer, chronic kidney disease, or neuroendocrine disorders—as well as those with abnormal levels of relevant biomarkers such as NSE and creatinine.